ArticleFrontiers in endocrinology2025
Hemoglobin glycation index and all-cause mortality in adults: insights from a decade-long prospective cohort study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hemoglobin glycation index correlates with the prognoses of critically ill patients with hyperlipidemia: a retrospective cohort study from the MIMIC-IV database.BMC endocrine disorders · 2026Article
- Association of hemoglobin glycation index with the severity and mortality of cardiovascular-kidney-metabolic syndrome: a population-based cohort study.Cardiovascular diabetology. Endocrinology reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The hemoglobin glycation index (HGI), an indicator of individual differences in glucose metabolism. This study undertakes a detailed 10-year cohort analysis to investigate the potential association between HGI and all-cause mortality in a Chinese adult population. Methods: Baseline data encompassing lifestyle and metabolic parameters were collected from 10,008 participants, with a subsequent 10-year follow-up. Following exclusions based on predefined criteria, 9,084 individuals were included in the final analysis. Participants were categorized into quartiles based on their HGI values. A suite of statistical tools, including Kaplan-Meier survival analysis, Cox proportional hazards models, restricted cubic splines (RCS), threshold effect models, and subgroup analyses, was employed to investigate the association between HGI and all-cause mortality. Results: During the 10-year follow-up period, a total of 514 all-cause mortality cases were recorded. Kaplan-Meier survival analysis identified the Q2 group as having the lowest mortality rate. Fully adjusted Cox proportional hazards models demonstrated significant associations, indicating higher all-cause mortality risks in participants with both extremely low and high HGI levels compared to the Q2 group. RCS analysis further illustrated a U-shaped relationship between HGI and all-cause mortality. Conclusions: In the Chinese population, both markedly elevated and significantly reduced HGI levels are associated with adverse impacts on long-term survival. Core tip: The aim of this study was to assess the association of Hemoglobin Glycation Index(HGI) with all-cause mortality in non-type 2 diabetic patients based on a 10-year cohort study from China. After COX regression, restricted cubic spline analysis, and subgroup analyses, it was found that a significant increase or decrease in HGI adversely affected long-term survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.